FDA Approves Peginterferon Beta-1a Intramuscular Injection for Relapsing Multiple Sclerosis
Click HERE to Subscribe for the MS Beacon Newsletter February 1, 2021 Marco Meglio The basis of the approval for…
Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years
Neurology . 2020 Dec 28;10.1212/WNL.0000000000011242. doi: 10.1212/WNL.0000000000011242. Online ahead of print. Click HERE to Subscribe for the MS Beacon Newsletter PMID: 33372028 …
Stuart Schlossman
Mayzent Aids Cognitive Processing Speed in SPMS Patients, Trial Suggests
Click HERE to Subscribe for the MS Beacon Newsletter Mayzent (siponimod) significantly improved cognitive processing speed in people with secondary progressive multiple…
Stuart Schlossman
FDA Approves Genentech’s Ocrevus (ocrelizumab) Shorter 2-Hour Infusion for Relapsing and Primary Progressive Multiple Sclerosis
Click HERE to Subscribe for the MS Beacon Newsletter · Approval based on data from the randomized, double-blind ENSEMBLE PLUS…
Stuart Schlossman
Learn of VUMERITY® (diroximel fumarate)
What is VUMERITY® (diroximel fumarate)? VUMERITY is a prescription medicine used to treat people with relapsing forms of multiple sclerosis (MS),…
Stuart Schlossman
Some MS Drugs Linked With Worse COVID-19 Outcomes
— Registry data looks at risks of hospitalization, ICU admission, ventilation by Judy George, Senior Staff Writer, MedPage Today September 28, 2020…
Stuart Schlossman
REDISCOVER WHAT S1P THERAPY CAN MEAN FOR YOUR MULTIPLE SCLEROSIS PATIENTS
An S1P Optimized to Target With Selectivity ZEPOSIA blocks the capacity of lymphocytes to egress from lymph nodes, reducing the…
Stuart Schlossman
Early Intensive MS Treatment Yields Better Outcomes Than Escalation Approach
September 23, 2020 Matt Hoffman Early intensive treatment was more effective in controlling disability progression over time compared with an…
Stuart Schlossman
More on the FDA Approval of Kesimpta, B-cell Targeting Therapy for Relapsing MS
The U.S. Food and Drug Administration (FDA) has approved Novartis‘ Kesimpta (ofatumumab) as a self-administered treatment for adults with relapsing forms of multiple sclerosis (MS),…
Stuart Schlossman
New Data Further Reinforce Genentech’s Ocrevus (ocrelizumab) as a Highly Effective Treatment for People With Multiple Sclerosis
* 75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease…
Stuart Schlossman
